These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7915703)

  • 1. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension.
    Albillos A; Lledó JL; Bañares R; Rossi I; Iborra J; Calleja JL; Garrido A; Escartin P; Bosch J
    Hepatology; 1994 Sep; 20(3):611-7. PubMed ID: 7915703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis.
    Lee WC; Lin HC; Yang YY; Hou MC; Lee FY; Chang FY; Lee SD
    Am J Gastroenterol; 2001 Apr; 96(4):1210-6. PubMed ID: 11316172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis.
    Sugano S; Kawafune T; Suzuki T; Kubota M; Okajima T; Sumino Y; Akita H
    Am J Gastroenterol; 1995 May; 90(5):788-93. PubMed ID: 7733089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function.
    Albillos A; Lledó JL; Rossi I; Pérez-Páramo M; Tabuenca MJ; Bañares R; Iborra J; Garrido A; Escartín P; Bosch J
    Gastroenterology; 1995 Oct; 109(4):1257-65. PubMed ID: 7557093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
    Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
    Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study.
    McCormick PA; Biagini MR; Dick R; Greenslade L; Chin J; Cardin F; Wagstaff D; McIntyre N; Burroughs AK
    Hepatology; 1992 Nov; 16(5):1180-6. PubMed ID: 1427656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
    De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S
    Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis.
    Feu F; Bordas JM; Luca A; García-Pagán JC; Escorsell A; Bosch J; Rodés J
    Hepatology; 1993 Nov; 18(5):1082-9. PubMed ID: 8225212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis.
    Lotterer E; Wengert A; Fleig WE
    Hepatology; 1999 Mar; 29(3):632-9. PubMed ID: 10051460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of urapidil and cimetidine on wedged hepatic venous pressure and systemic hemodynamics in cirrhotic patients with portal hypertension].
    Li S; Feng H; Zhu J; Zhong C; Leng X; Du R
    Zhonghua Wai Ke Za Zhi; 2000 Apr; 38(4):287-90. PubMed ID: 12828169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicardipine infusion improved hepatic function but failed to reduce hepatic venous pressure gradient in patients with cirrhosis.
    Iwao T; Toyonaga A; Ikegami M; Sugawara H; Sumino M; Takagi K; Oho K; Sakaki M; Ohkubo K; Inoue R
    Am J Gastroenterol; 1992 Mar; 87(3):326-31. PubMed ID: 1539567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation.
    Merkel C; Bolognesi M; Sacerdoti D; Bombonato G; Cavasin L; Gatta A
    Aliment Pharmacol Ther; 2005 Sep; 22(5):433-9. PubMed ID: 16128681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.
    Bosch J; Kravetz D; Rodes J
    Gastroenterology; 1981 Mar; 80(3):518-25. PubMed ID: 6108897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splenic Doppler impedance indices: influence of different portal hemodynamic conditions.
    Bolognesi M; Sacerdoti D; Merkel C; Gerunda G; Maffei-Faccioli A; Angeli P; Jemmolo RM; Bombonato G; Gatta A
    Hepatology; 1996 May; 23(5):1035-40. PubMed ID: 8621130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation.
    Fernández M; Pizcueta P; García-Pagán JC; Feu F; Cirera I; Bosch J; Rodés J
    Hepatology; 1993 Aug; 18(2):389-93. PubMed ID: 8340068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
    Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
    Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Portohepatic pressures, hepatic function, and blood gases in the combination of nitroglycerin and vasopressin: search for additive effects in cirrhotic portal hypertension.
    Iwao T; Toyonaga A; Ikegami M; Sumino M; Oho K; Sakaki M; Nishizono M; Tanikawa K
    Am J Gastroenterol; 1992 Jun; 87(6):719-24. PubMed ID: 1590307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.